Article Information
History
- April 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ahmed Zaqout1,2,*,
- Muna A. Almaslamani1,2,
- Hiam Chemaitelly3,4,5,
- Samar A. Hashim1,2,
- Ajithkumar Ittaman1,2,
- Abeir Alimam1,2,
- Fatma Rustom1,6,
- Joanne Daghfal1,
- Mohammed Abukhattab1,2,
- Sawsan AlMukdad3,4,
- Anvar Hassan Kaleeckal7,
- Ali Nizar Latif7,
- Adeel A. Butt2,5,10,
- Roberto Bertollini8,
- Abdullatif Al-Khal1,2,
- Ali S. Omrani1,2 and
- Laith J. Abu-Raddad3,4,5,9
- 1Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar
- 2Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
- 3Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar
- 4World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
- 5Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA
- 6Pharmacy Department, Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar
- 7Hamad Medical Corporation, Doha, Qatar
- 8Ministry of Public Health, Doha, Qatar
- 9Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
- 10Department of Medicine, Weill Cornell Medicine, New York, NY and Doha, Qatar
- ↵*Correspondence to Dr. Ahmed Zaqout, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar, e-mail: azaqout{at}hamad.qa
Posted April 22, 2022.
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar
